Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study aims to demonstrate non-inferiority of Pidogrel ® compared to Plavix ® in patients
with coronary disease:
- Primary Outcome Measures: measure of platelet reactivity by VerifyNow assay after 600 mg
loading dose or after the last maintenance dose (75 mg).
- Secondary Outcome Measures: Time to first occurrence of major cardio-vascular events
(MACE).
- Safety Criteria: severe bleeding (GUSTO scale).